Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Obesity

In brief

The primary objective of this study is to demonstrate that RAY1225 is superior to placebo for percent change in body weight.

Key facts

Study ID

NCT06893016

Run by

Guangdong Raynovent Biotech Co., Ltd

People needed

640

Starts

2025-06-15

Expected to finish

2026-09-15

Last updated by the study team

2025-07-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years.
• Body mass index ≥ 28 kg/m2 or ≥24kg/m² to <28 kg/m2 with at least 1 of the following weight-related comorbidities: a) Systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥85 mmHg, or the use of at least one antihypertensive medication to maintain normal blood pressure;b) Fasting triglycerides (TG) ≥1.70 mmol/L, fasting low-density lipoprotein cholesterol (LDL-C) ≥4.1 mmol/L, fasting high-density lipoprotein cholesterol (HDL-C) <1.04 mmol/L, or the need for at least one lipid-lowering treatment to maintain normal lipid levels; c) Obstructive sleep apnea syndrome; d) Fatty liver; e) Cardiovascular disease; e) Polycystic ovary syndrome.
• History of at least 1 self-reported unsuccessful attempt at weight loss by diet and exercise.

You may not qualify if…

• Obesity known to be caused by monogenic mutations, other diseases, or medications.
• Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2.
• A history of moderate to severe depression at any time in the past or a score of ≥15 on the PHQ-9 questionnaire at screening; a history of bipolar disorder, schizophrenia, or other severe psychiatric disorders.
• A history of organ transplantation (excluding corneal transplant), or being currently prepared to undergo organ transplantation.
• Plans to quit smoking during the study period
• Allergic constitution (allergic to multiple medications or foods), or those known to be allergic to RAY1225, GLP-1 receptor agonists, or GLP-1 related drugs.

Where it is running

• Peking University People's Hospital — Beijing, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.